Vaccinex stock at 0.92 USD as melanoma findings remain in focus
Published on 11/06/2026 at 01:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSVaccinex stock and pipeline
- Vaccinex is a clinical-stage biotechnology company developing targeted antibody therapies for serious diseases.
- The company's pipeline includes pepinemab, a SEMA4D antibody platform and the ActivMAb discovery platform.
Vaccinex stock traded at 0.92 US dollars on OTC Markets at 12:31 p.m. ET on Thursday, November 5. The quote provides a current market reference for investors following the clinical-stage biotechnology company.
Melanoma findings remain relevant
Vaccinex has recently reported findings from a melanoma study involving pepinemab. The study examined immune changes in the tumor environment, while the findings did not establish clinical efficacy.
Vaccinex's development work centers on targeted biotherapeutics for cancer, neurodegenerative diseases and autoimmune disorders. Its pipeline includes pepinemab, the SEMA4D antibody platform and the ActivMAb antibody discovery platform.
Investors can follow the real-time quote of Vaccinex stock for further trading updates.
Vaccinex market reference
- Company: Vaccinex, Inc.
- ISIN: US9186403013
- Ticker: VCNX
- Trading venue: OTC Markets
- Quote: 0.92 US dollars at 12:31 p.m. ET on Thursday, November 5, 2026
US biotechnology shares are tracked against the S&P 500, which provides the broader market context.
More news and analyses on Vaccinex stock are available in the company topic.
